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SUMMARY
A woman in her 30s presented to the dermatology
clinic with widespread, pruritic, red papules and plaques
involving the ears, trunk and extremities. The rash
developed a few days after receiving her second injection
of secukinumab, which was initiated for recalcitrant
Hurley stage III hidradenitis suppurativa. Investigations
revealed a psoriasiform drug hypersensitivity reaction
secondary to secukinumab. In this report, we describe
the clinical course, histopathological correlation and
treatment of this rarely documented reaction.

BACKGROUND

Secukinumab is a human monoclonal antibody that
binds to interleukin-
17A (IL-
17A), a proinflammatory cytokine that has been implicated in the
pathogenesis of a wide range of disorders, including
psoriasis and psoriatic arthritis. Recent evidence
suggests that secukinumab may additionally serve as
an effective therapy for patients with hidradenitis
suppurativa (HS).1 In the face of expanding clinical indications and increasing usage of this biologic
therapy, adverse effects such as hypersensitivity skin
reactions have been reported in a subset of treated
patients.2
We report a case of a psoriasiform drug hypersensitivity reaction secondary to secukinumab that
necessitated prompt discontinuation of the drug
and treatment with a prolonged course of oral
corticosteroids.

CASE PRESENTATION
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A woman in her 30s presented with a widespread,
pruritic, rash involving the ears, trunk and extremities of approximately 6 weeks’ duration. The
lesions first developed a few days after her second
300 mg weekly loading dose of secukinumab, which
was originally initiated for recalcitrant Hurley stage
III HS (figure 1).
Physical examination revealed numerous
erythematous, scaly papules on the bilateral ears,
upper chest, inframammary folds, bilateral upper
extremities and abdomen (including umbilicus).
Large, well-demarcated, erythematous, oedematous
plaques were observed to involve the bilateral axillary folds symmetrically (figure 2). Her vital signs
were stable, and she denied recent facial swelling
or urticaria.

INVESTIGATIONS

A punch biopsy obtained from the right flank
revealed psoriasiform epidermal hyperplasia with

spongiosis, lymphocyte exocytosis and serous
crusting with ample neutrophils in the stratum
corneum. A dense superficial perivascular and
interstitial infiltrate of lymphocytes with numerous
eosinophils was also observed (figure 3). Periodic
acid-Schiff stain was negative for fungal elements.
In the context of the clinical findings, a diagnosis
of a psoriasiform drug hypersensitivity reaction to
secukinumab was made.

DIFFERENTIAL DIAGNOSIS

Given the notable involvement of skin folds and
pathology displaying psoriasiform epidermal
hyperplasia with spongiosis and prominent eosinophils, alternative diagnoses such as secukinumab-
induced paradoxical psoriasiform eruption and
symmetrical drug-related intertriginous and flexural exanthema were also considered. However,
paradoxical psoriasiform eruption was deemed
less likely considering the morphology of the
lesions as well as the numerous eosinophils seen
on histology. In addition, given that our patient
did not exhibit gluteal or inguinal involvement,
symmetrical drug-related intertriginous and flexural exanthema was felt to be inconsistent with
the clinical presentation.

TREATMENT

Secukinumab was discontinued, and because the
mean half-life of this biologic agent ranges from
22 to 31 days, an 8-week prednisone taper starting
at 80 mg daily and incrementally decreased by
10 mg each week was initiated with resolution of
the rash. Following completion of this prednisone
taper, the patient experienced a mild recurrence
of her original rash, which fully resolved without
recurrence after an additional 4 weeks of prednisone was administered.

OUTCOME AND FOLLOW-UP

At 1 year following discontinuation of secukinumab, the patient’s HS remains inadequately
controlled after failing multiple other biologic,
non-
biologic and surgical treatments, including
various antibiotic regimens, adalimumab, infliximab, certolizumab, apremilast, ustekinumab,
spironolactone, metformin and surgical excision
of numerous lesions involving the posterior neck,
axillary folds, groin and buttocks.
Currently, her HS is partially controlled on high-
dose, high-frequency infliximab infusions with imminent plans to initiate concurrent oral tofacitinib.
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Figure 1 Visual timeline representing chronology of hypersensitivity
reaction and prior medication use.

DISCUSSION

Secukinumab is a selective IL-17A inhibitor that is US Food
and Drug Administration-
approved for the treatment of
plaque psoriasis, psoriatic arthritis, ankylosing spondylitis and
non-radiographic axial spondyloarthritis. It is also increasingly
being used in the off-label treatment of other inflammatory
skin conditions, including HS. Secukinumab is typically well-
tolerated and demonstrates a favourable safety profile with
nasopharyngitis and upper respiratory infections listed as the
most frequent side effects.
To our knowledge, we present the fifth documented
case of a cutaneous delayed-
type hypersensitivity reaction
(type IV reaction) to secukinumab. Shibata et al described a
52-year-old woman with psoriatic arthritis who developed a
papular eruption 3 days after the fourth dose of secukinumab.
Skin biopsy confirmed a drug hypersensitivity eruption, and
reintroduction of the medication prompted a relapse of the
dermatitis.3 Another report described a similar case in which
a psoriasis patient developed a widespread papular eruption
after the fourth dose of secukinumab. Skin biopsy exhibited
‘focal parakeratosis, exocytosis of lymphocytes, rare apoptotic
keratinocytes, and a perivascular infiltrate of lymphocytes and
rare eosinophils in the upper dermis’.4 The patient’s condition
gradually improved with systemic corticosteroids and discontinuation of the offending drug. In a third report, Wong and
Chung described a 24-year-old woman with axial spondyloarthritis who developed a maculopapular eruption of the lower
extremities in association with mild liver dysfunction after her

Figure 3 Histological images of cutaneous delayed-type
hypersensitivity (type IV) reaction to secukinumab. Low-power (A) and
high-power views (B) showing regular epidermal hyperplasia with
spongiosis and serous crusting with ample neutrophils in the stratum
corneum, as well as a superficial perivascular and interstitial infiltrate of
lymphocytes and numerous eosinophils. Periodic acid-Schiff stain was
negative for fungal elements (not shown).
15th dose of secukinumab. No skin biopsy was performed.
Her condition spontaneously normalised after discontinuation
of secukinumab.5
Most recently, Darrigade et al described a case of a 51-year-old
woman with psoriatic arthritis who, after the second administration of secukinumab, developed pruritic, erythematous
skin lesions on the abdomen and breasts. A biopsy was not
performed. However, patch testing revealed a positive reaction to secukinumab, and resolution was noted after 3 weeks
of treatment with antihistamines and oral and topical corticosteroids.6 Although patch testing was not performed in our
case, confirmatory histopathology was obtained, which specifically implicates a psoriasiform pattern of drug hypersensitivity. Furthermore, the Naranjo algorithm scoring for our
patient, a questionnaire designed to assess the probability of
whether a suspected adverse drug reaction is due to the drug
rather than alternative aetiologies, was seven and compatible
with a probable adverse drug reaction to secukinumab.
Of note, there have also been reports describing pustular
exacerbations of plaque psoriasis treated with secukinumab
as well as secukinumab-
induced new-
onset psoriasiform
eruptions involving the fingertips and nails.7 8 Skin biopsies
were not performed in these cases, which makes histological comparison to our case difficult. However, the decidedly
different clinical features observed in these cases suggests that
these represent entities distinct from the hypersensitivity reaction described by our group and others.
Furthermore, it is well known that HS and psoriasis are
chronic inflammatory skin diseases that share common pathogenetic mechanisms involving tumour necrosis factor-
alpha
and IL-17. The two conditions have been known to co-occur,
both on their own as well as part of syndromes, such as SAPHO
(synovitis-acne-pustulosis-hyperostosis-osteitis) and PsAPASH
(psoriatic arthritis, pyoderma gangrenosum, acne and hidradenitis suppurativa). Despite the immunopathogenetic similarities

Learning points
Figure 2 Clinical images of cutaneous delayed-type hypersensitivity
(type IV) reaction to secukinumab. (A, B) Indurated, erythematous, scaly,
crusted plaques with associated maceration on the bilateral axillary
folds, as well as scattered erythematous papules and papulonodules on
the abdomen and bilateral inframammary folds; taken 4 months after
surgical excision of axillary hidradenitis suppurativa lesions and 6 weeks
after initial onset of the eruption. (C, D) Resolution of the cutaneous
hypersensitivity reaction 6 weeks after discontinuation of secukinumab
and initiation of a prolonged prednisone taper.
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► Secukinumab, a selective interleukin-17A inhibitor, has

increasing off-label uses, including the treatment of
hidradenitis suppurativa.
► Secukinumab may rarely cause delayed-type hypersensitivity
reactions.
► The complex nature of adverse reactions to biologic agents,
including secukinumab, illustrates the need for a high index
of suspicion and prompt identification and response to
prevent unfavourable outcomes.
Konda S, et al. BMJ Case Rep 2022;15:e249684. doi:10.1136/bcr-2022-249684

BMJ Case Rep: first published as 10.1136/bcr-2022-249684 on 17 May 2022. Downloaded from http://casereports.bmj.com/ on June 21, 2022 at Henry Ford Hospital. Protected by copyright.

Case report

and comorbid nature seen in HS and psoriasis, multiple factors,
including characteristic clinical and histopathological features,
timing of eruption and resolution with discontinuation of the
offending drug, indicate that this patient experienced a type
IV hypersensitivity reaction, not a co-occurrence of psoriasis.
Biologics, including monoclonal antibodies like secukinumab, have the potential to be immunogenic and can lead
to the formation of antidrug antibodies that can precipitate
undesirable effects, including decreased therapeutic efficacy
or even drug hypersensitivity reactions. Secukinumab has
been shown to be associated with a lower incidence of clinical immunogenicity in comparison to other biologics, such as
adalimumab and infliximab.9 Nevertheless, clinicians should
be aware that secukinumab still carries the potential to trigger
significant cutaneous eruptions that mandate timely drug
discontinuation and potentially administration of corticosteroids for resolution.
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